Adjust for infinite possibilities.

With the revolutionary Light Adjustable Lens™

Now with ActivShield™ Technology

ActivShield is a revolutionary UV protection layer built into the newly updated Light Adjustable Lens

How the Light Adjustable Lens Works

The Light Adjustable Lens (LAL) is the first and only lens that is fully adjustable after cataract surgery.

Unlike traditional cataract surgery and lens implant options, the LAL gives surgeons the opportunity for multiple lens adjustments after surgery. UV light treatments after surgery correct refractive error and dial in optimized vision.

1 Perform a standard cataract implant procedure using the RxSight Light Adjustable Lens.

The LAL is implanted using standard cataract surgery techniques. However, because the lens will be adjusted using UV light after surgery and healing has occurred, surgeons can simplify their pre-surgical diagnostic workflow and reduce the anxiety and burden on patients.

2 Determine refractive error with a standard refraction technique, optimizing refraction with patient input after healing is complete.

Standard refraction techniques can be used after surgery to measure refractive error for LAL patients. This process can be more precise than ever, accounting for lens shift and refractive changes during the healing process, through the LAL’s ability to be adjusted weeks after surgery. Unlike standard lens implants, patients have direct input into their refractive correction as they experience and test vision options during the light adjustment phase.

3 Refractive error is corrected with the RxSight Light Delivery Device (LDD).

The LDD delivers targeted UV light to shape the LAL and offer precise adjustment and vision for each patient. Surgeons can adjust the lens over a series of treatments to ensure each patient achieves vision that matches their goals and expectations.

What Makes the Light Adjustable Lens Different

UCVA Worse Than 20/32

The LAL outperforms toric lenses for treating astigmatism.

UCVA at 6 Months Postop

The LAL offers LASIK-like accuracy in cataract surgery.

Optimized vision for patient satisfaction

The LAL provides optimized vision for patient satisfaction.

Adjust for Improved Clinic Flow

The LAL's flexibility can help simplify both the pre- and post-operative workflow of your practice in the following ways:

Diagnostics

Simplifies pre-surgical diagnostic workflow by extending the ability to adjust the lens refraction after surgery

Reduced patient anxiety

Reduces patient anxiety by offering them control and choice in their final vision outcome

Small clinic footprint

The LDD's small clinic footprint is simple to incorporate into your post-surgical workflow

Adjust for Better Patient Outcomes

Many patients can benefit from the exciting opportunities created by the LAL. Patients who may be candidates include those who are:

Optimize

Looking to optimize their vision and outcomes

Appointments

Able to make and keep the additional 3 to 5 appointments needed for optimal vision with the RxSight LAL

Astigmatism

Found to have pre-existing corneal astigmatism of ≥ 0.75 diopters

UV glasses

Able to comply with wearing UV protective glasses until final light treatment

Learn More About the Light Adjustable Lens

If you're ready to revolutionize cataract surgery at your practice, fill out the form below to receive our complete guide to the LAL.

Transmitting

Thanks! Please check your email...

A link will be delivered to your email address that provides a download of the RxSight LAL Guide for Healthcare Professionals. If you don't receive anything, please be sure to check your junk or spam inbox.

The LAL outperforms toric lenses for treating astigmatism.

The ability to treat 0.50 D of postoperative cylinder makes the RxSight LAL the only IOL in the United States approved to correct this level of vision-altering astigmatism.

Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.

These percentages are results from the pivotal studies for each lens. The Tecnis toric lens was studied in a prospective, multicenter, two-armed, bilateral study of four Tecnis toric models in 269 patients. The primary effectiveness endpoint was the mean percent reduction in cylinder. The safety and effectiveness of the AcrySof toric lens were studied in a randomized clinical study of three models (SA60TT) and a control lens (SA60AT) in 421 patients.


References

  1. RxSight P160055: FDA Summary of Safety and Effectiveness Data. 2017.
  2. Tecnis® Toric PMA P980040/S039: FDA Summary of Safety and Effectiveness Data. 2013.
  3. AcrySof® Toric P930014/S45: FDA Summary of Safety and Effectiveness Data. 2011.
  4. Watanabe K, Negishi K, Kawai M, et al. Effect of experimentally induced astigmatism on functional, conventional, and low-contrast visual acuity. J Refract Surg. 2013;29(1):19-24.

The LAL offers LASIK-like accuracy in cataract surgery.

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.


References

  1. RxSight P160055: FDA Summary of Safety and Effectiveness Data. 2017.
  2. Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-1234.

The LAL provides optimized vision for patient satisfaction.

LAL patients saw nearly as well without glasses (UCVA) as control patients did with glasses (BCVA).

Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to enhanced vision and patient satisfaction.


References

  1. Data on file, RxSight. Clinical study report 002-03.

Contact Us

Customer Experience
(Orders): 833.888.7974
Corporate: 949.521.7830
Sales Inquiries: 949.421.5460

 
Transmitting

Thank you!

We will connect with you shortly. We appreciate your interest in RxSight!

You are leaving RxSight.com

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. RxSight does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to RxSight. Click “Continue” to leave site or “Return to RxSight.com” to close this window and return to RxSight.com.

You are leaving RxSight.com

The list of healthcare providers on the “Find a Physician” webpage is intended for informational purposes only and in no way represents an endorsement, referral, or recommendation from RxSight. The list is merely a tool to help identify certified and trained RxSight Light Adjustable Lens providers, and no compensation has been received or paid in exchange for listing the healthcare providers.

Selection of a healthcare provider is the patient’s responsibility and should be made with careful consideration. RxSight makes no representations or warranties and assumes no liability resulting from patient’s selection of a healthcare provider.